Quantcast
Last updated on April 23, 2014 at 17:36 EDT

Shire on Track for Double Digit Full Year Earnings Growth

October 25, 2012

DUBLIN, October 25, 2012 /PRNewswire/ –

Advancing Late Stage Pipeline of new Growth Opportunities

Shire (LSE: SHP, NASDAQ: SHPG) announces results for the three months to September 30,
2012.

                                                            Reported       CER
        Financial Highlights                      Q3 2012   Growth (1)    Growth(2)

        Product sales                       $1,055 million         +4%         +6%

        Product sales excluding ADDERALL XR   $952 million        +10%        +13%

        Total revenues                      $1,100 million         +1%         +4%

        Non GAAP operating income             $325 million         -5%

        US GAAP operating income              $273 million         +7%
        Non GAAP diluted earnings per ADS            $1.36         +6%
        US GAAP diluted earnings per ADS             $1.19        +17%

        Non GAAP cash generation              $355 million        +20%

        Non GAAP free cash flow               $261 million        +90%
        US GAAP net cash provided by operating
        activities                            $288 million        +61%

(1) Percentages compare to equivalent 2011 period.

(2) Percentages compare to equivalent 2011 period on a constant exchange rate (“CER”)
basis, which is a Non GAAP measure.

The Non GAAP financial measures included within this release are explained on page 25,
and are reconciled to the most directly comparable financial measures prepared in
accordance with US GAAP on pages 20 – 24.

Angus Russell, Chief Executive Officer, commented:

“Shire’s business is progressing well. This quarter we grew Non GAAP earnings per ADS
by 6% after increasing our investment in R&D by over 20% to fund our increasingly late
stage pipeline. We continue to generate strong cash flows (up 20% to over $350 million in
the quarter), which will support our future growth.

“The ADHD market is one of the fastest-growing major therapeutic categories in the US
and our lead product VYVANSE continues to gain share and generated strong prescription
growth in the US despite the entry of additional generics in the ADHD market. We are
advancing our preparations for the potential approval and launch of VYVANSE in Europe,
where it will be called ELVANSE. Our rare disease business also continues to grow, with
FIRAZYR performing strongly following its US launch. DERMAGRAFT product sales were
impacted by the re-engineering of key areas of the Regenerative Medicine business,
including an ongoing restructuring of the sales and marketing organization and the
implementation of a new commercial model, all of which is expected to position the product
for future sales growth. We anticipate that the run rate for DERMAGRAFT revenues will
recover during 2013.

“In our advancing pipeline we have late stage studies for Lisdexamfetamine dimesylate
(“LDX” – the active ingredient in VYVANSE) in major depressive disorder ongoing, we are
planning to initiate our Phase 3 program for binge eating disorder around the turn of the
year and following discussions with the FDA, we plan to initiate Phase 3 studies in
negative symptoms of schizophrenia in the near future. We’ve also identified potential new
indications for FIRAZYR and DERMAGRAFT. Our intrathecal trials for Hunter CNS, SanFilippo
A and Metachromatic Leukodystrophy are also progressing well.

“Shire remains on track to deliver double digit full year earnings growth in 2012. We
are increasingly confident in our ability to meet our target of delivering sound earnings
growth in 2013 and deliver increased growth beyond that.”

FINANCIAL SUMMARY

Third Quarter 2012 Unaudited Results

                               Q3 2012                          Q3 2011
                                              Non                              Non
                   US GAAP   Adjustments     GAAP   US GAAP   Adjustments     GAAP
                        $M            $M       $M        $M            $M       $M
        Total
        revenues     1,100             -    1,100     1,086             -    1,086
        Operating
        income         273            52      325       255            86      341
        Diluted
        earnings
        per ADS      $1.19         $0.17    $1.36     $1.02         $0.26    $1.28

        - Product sales were up 4% to $1,055 million (Q3 2011: $1,018 million). On a
          CER basis product sales were up 6%. This quarter, sales were affected by $28 million
          of unfavorable foreign exchange, primarily in our Human Genetic Therapies ("HGT")
          business (up 9% on a reported basis, up 16% on a CER basis), particularly due to
          weaker European currencies.

Product sales excluding ADDERALL XR(R) were up 10% (13% on a CER basis), as we saw
strong growth from VYVANSE(R) (up 24% to $247 million), VPRIV(R) (up 16% to $75 million),
INTUNIV(R) (up 23% to $69 million) and FIRAZYR(R) (up to $30 million from $7 million in Q3
2011). Product sales growth was held back by DERMAGRAFT(R) (down 33% to $34 million), due
to the ongoing restructuring of the Regenerative Medicine sales and marketing
organization.

ADDERALL XR product sales were down 32% to $102 million due to lower prescription
volumes and higher sales deductions (Q3 2011 benefited from significantly lower sales
deductions following a lowering of the estimate of inventory in the US retail pipeline). A
generic version of ADDERALL XR was approved late in Q2 2012.

        - Total revenues were up 1% (up 4% on a CER basis) as the growth in product
          sales was offset, as expected, by lower royalties, particularly ADDERALL XR royalties
          received from Impax Laboratories Inc. ("Impax") following the launch of Actavis Inc.'s
          ("Actavis") generic product.
        - On a Non GAAP basis:

Operating income was down 5% to $325 million (Q3 2011: $341 million), as combined
total operating costs increased at a slightly higher rate (4%) than total revenues.
Research and development (“R&D”) expenditure was up 22% due to our investment in new uses
for LDX[(1)] and other early and late stage pipeline programs. Selling, General and
Administrative (“SG&A”) expenditure decreased 5% in Q3 2012, reflecting our continuing
focus on effective cost management and some favorable foreign exchange impact.

On a US GAAP basis:

Operating income was up 7% to $273 million (Q3 2011: $255 million), as Q3 2011
included certain in-process R&D (“IPR&D”) impairment charges and higher costs related to
acquisition and integration activities.

        - Non GAAP diluted earnings per American Depository Share ("ADS") increased
          6% to $1.36 (Q3 2011: $1.28), as a lower Non GAAP effective tax rate of 18% (Q3 2011:
          25%) more than offset lower Non GAAP operating income.

On a US GAAP basis diluted earnings per ADS increased 17% to $1.19 (Q3 2011: $1.02),
due to higher operating income and a lower US GAAP effective tax rate of 15% (Q3 2011:
27%).

        - Cash generation, a Non GAAP measure, grew strongly by 20% to $355 million
          (Q3 2011: $296 million).

Free cash flow, also a Non GAAP measure, was up 90% to $261 million (Q3 2011: $138
million) due to higher cash generation, lower cash tax payments and lower capital
expenditure in Q3 2012 compared to Q3 2011.

On a US GAAP basis, net cash provided by operating activities was up 61% to $288
million (Q3 2011: $179 million).

        - Reflecting our strong cash generation, net cash at September 30, 2012 was
          $213 million (December 31, 2011: net debt of $488 million).
        - LDX, currently marketed as VYVANSE in the US for the treatment of Attention
          Deficit Hyperactivity Disorder ("ADHD").

        - Shire has a strong balance sheet and continued robust cash generation, and
          considers the efficient use of capital on behalf of shareholders as an important
          objective.
        - We are initiating a share buy-back program of up to $500 million. This
          buy-back program will not constrain the Company's ability to execute its strategy of
          generating shareholder value through organic growth and acquisitions which further
          enhance the quality and growth potential of the business.
          This buy-back program is within the terms of the authority granted by shareholders
          at the 2012 AGM. The market will be notified in accordance with the listing rules if
          and when purchases are effected.

OUTLOOK

Shire has performed well in the year so far and is on track to deliver double-digit
full-year earnings growth in 2012. We now expect product sales growth to be around 12% for
the full year. This reflects our expectation of continued lower sales in the fourth
quarter for DERMAGRAFT while we restructure our Regenerative Medicine commercial
operations, and also the foreign exchange impact we have absorbed on some of our products
this quarter.

We now expect an improved contribution from royalties and other revenues, of
approximately 15% to 20% lower than last year, a change from our previous guidance of 25%
to 35% lower. This reflects the recent settlement reached with GSK which will result in
Shire recording additional, one-time royalty income of $38 million in Q4 2012.

We continue to anticipate some marginal dilution of Non GAAP gross margins in the full
year.

We are continuing our investment in the long term prospects of the business and now
expect year on year growth of combined Non GAAP R&D and SG&A expenditure to trend towards
the lower end of our previous guidance of 10-12%.

We expect our full year Non GAAP effective tax rate to be in the range of 18%-20%, as
previously guided.

Overall, we remain on track to deliver double digit full year earnings growth in 2012.

In 2013, we expect revenues from ADDERALL XR (including its associated royalty) to
reduce as we absorb the full year impact of the recent launch of a generic competitor. We
will be investing in several late stage clinical trials and with careful management of our
cost base and prioritization of other investments, we are increasingly confident in our
ability to meet our target of delivering sound earnings growth in 2013 and deliver
increased growth beyond that.

THIRD QUARTER 2012 AND RECENT PRODUCT AND PIPELINE DEVELOPMENTS

Products

VPRIV – for the treatment of Type 1 Gaucher disease

        - In October 2012 Shire submitted its response to the matters raised by the
          US Food and Drug Administration ("FDA") in respect of production of VPRIV drug
          substance at Lexington, and continues to work closely with the FDA towards a
          satisfactory resolution.

Notwithstanding the ongoing discussions with the FDA, Shire continues to supply VPRIV
to US patients through its existing approved US manufacturing facilities and has the
capacity to meet the anticipated demand for VPRIV from current and new patients both in
the US and globally.

DERMAGRAFT – for the treatment of Diabetic Foot Ulcers (“DFU”) in Canada

        - On September 5, 2012 Shire announced that DERMAGRAFT had received
          regulatory approval from Health Canada as a class IV medical device for the treatment
          of DFU. Shire intends to make DERMAGRAFT available in Canada in Q1 2013. This approval
          is an important first step for Shire Regenerative Medicine as it continues to develop
          its international expansion strategy.

VYVANSE – for the treatment of ADHD

        - On September 12, 2012 Shire announced that the FDA has accepted the filing
          for review of a supplemental New Drug Application for VYVANSE. Shire is seeking
          approval of VYVANSE as a maintenance treatment in children and adolescents aged 6 to
          17 years with ADHD. There are currently no stimulants approved for maintenance
          treatment in children and adolescents aged 6 to 17 years with ADHD. The FDA has issued
          a Prescription Drug User Fee Act action date of April 29, 2013.

Pipeline

LDX – for the treatment of Major Depressive Disorder (“MDD”)

        - The Phase 3 program is ongoing with headline data expected in the second
          half of 2013.

SPD602 – for the treatment of chronic iron overload requiring chelation therapy

        - A Phase 2 trial has been initiated to evaluate the safety and efficacy of
          SPD602 in patients with tranfusional iron overload and whose primary diagnosis is
          hereditary or congenital anemia.

HGT1110 for the treatment of Metachromatic Leukodystrophy (“MLD”)

        - In Q3 2012, Shire initiated a Phase 1/2 clinical trial for the treatment
          of MLD with HGT1110, an enzyme replacement therapy which is delivered intrathecally.
          This product has been granted orphan designation in the US and the EU. There is no
          currently available therapy for MLD.

FIRAZYR – for the treatment of ACE inhibitor-induced angioedema

        - An investigator sponsored trial into the use of FIRAZYR for the treatment
          of ACE inhibitor-induced angioedema was recently completed in the EU. The results of
          the investigator sponsored trial were positive and the investigator is preparing an
          article for publication. ACE inhibitor-induced angioedema is a rare and potentially
          life-threatening side effect of ACE inhibitor therapy, with approximately 130,000
          cases per year in the US and 160,000 in the EU and no currently approved therapy.
          Shire is reviewing the necessary steps likely to be required to extend FIRAZYR's label
          to include this indication in each of the US and EU.

DERMAGRAFT – for the treatment of Epidermolysis Bullosa (“EB”)

        - Shire expects Phase 3 clinical trials to commence towards the end of 2012.
          EB is a rare genetic disorder for which there is no approved therapy.

OTHER DEVELOPMENTS

Telethon Institute of Genetics and Medicine (“TIGEM”) collaboration

        - On October 24, 2012 Shire announced that it had entered into a long-term,
          broad based, multi-indication research collaboration in rare diseases with Fondazione
          Telethon, a major Italian biomedical charitable foundation, for several research
          projects carried out at TIGEM that collectively research 13 undisclosed rare disease
          indications that have the potential to add multiple novel therapeutic candidates to
          the early stage pipeline.

License agreement with IGAN Biosciences, Inc. (“IGAN”)

        - On October 24, 2012 Shire acquired a worldwide exclusive license from IGAN
          to develop and commercialize protease-based therapeutics for the treatment of IgA
          nephropathy, a rare kidney disease. This pre-clinical opportunity is an appealing
          strategic fit for Shire's rare disease portfolio.

Legal Proceedings

INTUNIV patent litigation

        - On September 6, 2012 Shire announced that it had settled all pending
          litigation with Anchen Pharmaceuticals, Inc. ("Anchen") and TWi Pharmaceuticals, Inc.
          ("TWi") in connection with TWi's Abbreviated New Drug Application for a generic
          version of INTUNIV. As part of the settlement, Anchen was given a license to make and
          sell its generic version of INTUNIV from July 1, 2016, or earlier in certain
          circumstances. Also, Shire may authorize Anchen to sell authorized generic versions of
          INTUNIV supplied by Shire. This settlement had no effect on the ongoing lawsuit
          against Actavis and Teva Pharmaceuticals USA, Inc. ("Teva"), in connection with their
          attempts to market generic versions of Shire's INTUNIV. A bench trial against Actavis
          and Teva was held in the US District Court for the District of Delaware from September
          17 to September 20, 2012. The post trial briefing of the parties to the judge is
          scheduled to conclude by November 1, 2012 and no decision has yet been given.

BOARD AND COMMITTEE CHANGES

        - The Board of Directors announces today the retirement in 2013 of Chief
          Executive Angus Russell after 13 years with the Company and 32 years in the
          pharmaceutical industry. Flemming Ornskov MD, MBA, MPH has been appointed to succeed
          Angus and will join the Shire Board as Chief Executive Designate on January 2, 2013,
          from Bayer. A handover period of several months after Flemming joins the Board will
          see Angus and Flemming working together to ensure a smooth transition before Flemming
          becomes CEO on April 30, 2013, the date of the Shire Annual General Meeting (see
          separate press release for more detail).
        - Dr. Steven Gillis, Ph.D. has joined the Board of Directors on October 1, 2012.
          Dr. Gillis has also been appointed as a member of the Science & Technology Committee
          and Remuneration Committee with effect from October 1, 2012.

ADDITIONAL INFORMATION

The following additional information is included in this press release:

                                                                  Page
        Overview of Third Quarter 2012 Financial Results            7
        Financial Information                                      11
        Non GAAP Reconciliations                                   20
        Notes to Editors                                           25
        Safe Harbor Statement                                      25
        Explanation of Non GAAP Measures                           25
        Trademarks                                                 26

Dial in details for the live conference call for investors 13:00 BST/8:00 EDT on
October 25, 2012:

UK dial in: +(0)808-237-0030

US dial in: +1-866-928-7517 or +1-718-873-9077

International dial in: +44(0)203-139-4830

Password/Conf ID: 99054603#

Live Webcast: http://www.shire.com/shireplc/en/investors

OVERVIEW OF THIRD QUARTER 2012 FINANCIAL RESULTS

1. Product sales

For the three months to September 30, 2012 product sales increased by 4% to $1,055
million (Q3 2011: $1,018 million) and represented 96% of total revenues (Q3 2011: 94%).

                                                                          US Exit
                                            Year on year growth            Market
                                                                       Share[(1)]
        Product sales          Sales $M   Sales      CER   US Rx(1)]
        VYVANSE                   247.1     +24%      +24%       +16%         17%
        REPLAGAL(R)               121.7      -6%       +2%     n/a(3)      n/a(3)
        ELAPRASE(R)               110.5      +1%       +8%     n/a(2)      n/a(2)
        LIALDA/MEZAVANT(R)        104.4     +16%      +17%        +6%         22%
        VPRIV                      74.9     +16%      +21%     n/a(2)      n/a(2)
        INTUNIV                    69.0     +23%      +23%       +27%          4%
        PENTASA(R)                 67.0     +20%      +20%        -4%         14%
        FOSRENOL(R)                38.1      -6%       -1%       -19%          5%
        DERMAGRAFT                 33.7     -33%      -33%     n/a(2)      n/a(2)
        FIRAZYR                    30.3    +321%     +331%     n/a(2)      n/a(2)
        OTHER                      55.6     -16%      -11%        n/a         n/a
        Excluding ADDERALL XR     952.3     +10%      +13%
        ADDERALL XR               102.2     -32%      -32%       -17%          5%
        Total                   1,054.5      +4%       +6%

(1) Data provided by IMS Health National Prescription Audit (“IMS NPA”). Exit market
share represents the average monthly US market share in the month ended September 30,
2012.

(2) IMS NPA Data not available.

(3) Not sold in the US in Q3 2012.

VYVANSE – ADHD

VYVANSE product sales showed strong growth in Q3 2012, up 24% compared to Q3 2011, as
a result of higher prescription demand (up 16% compared to Q3 2011) and the effect of a
price increase taken since Q3 2011. These positive factors were partially offset by
destocking in Q3 2012.

REPLAGAL – Fabry disease

Reported REPLAGAL sales were impacted by unfavorable foreign exchange (amounting to
approximately $10 million), primarily due to weaker European currencies in Q3 2012
compared to Q3 2011 and Q2 2012. On a CER basis, sales continued to grow through the
treatment of both naive patients and those switching from FABRAZYME.

ELAPRASE- Hunter syndrome

Reported ELAPRASE sales in Q3 2012 were affected by weaker European currencies
(affecting reported product sales by approximately $8 million) and the timing of shipments
to markets with large, infrequent orders. This includes Brazil where a large shipment was
delayed in Q3 and will now occur in Q4. On a CER basis, ELAPRASE product sales increased
and patients on therapy continue to grow across all regions in which ELAPRASE is sold.

LIALDA/MEZAVANT – Ulcerative colitis

Product sales for LIALDA/MEZAVANT increased in Q3 2012 as a result of higher US
prescription demand and the effect of a price increase taken since Q3 2011. These positive
factors were partially offset by the effect of higher US sales deductions and the effect
of lower priced imports into certain European markets.

VPRIV – Gaucher disease

VPRIV product sales growth was driven by the treatment of new patients, being both
naive patients and switches from CEREZYME. Reported VPRIV sales were also impacted by
unfavorable foreign exchange (approximately $3 million).

INTUNIV – ADHD

INTUNIV product sales were up 23% in Q3 2012, primarily driven by strong growth in US
prescription demand (up 27% compared to Q3 2011), and the effect of price increases taken
since Q3 2011. These positive factors were partially offset by higher sales deductions in
Q3 2012 compared to Q3 2011.

PENTASA – Ulcerative colitis

PENTASA product sales benefited from price increases taken since Q3 2011 and the
effect of destocking in Q3 2011 which was not repeated in Q3 2012. These positive factors
were partially offset by higher sales deductions in Q3 2012 as compared to Q3 2011.

FOSRENOL – Hyperphosphatemia

Product sales for FOSRENOL decreased by 6% as lower US prescription demand and higher
sales deductions in Q3 2012 offset the effect of a price increase taken since Q3 2011.
Product sales of FOSRENOL outside the US were lower than Q3 2011 primarily due to the
effect of unfavorable foreign exchange.

DERMAGRAFT – DFU

DERMAGRAFT product sales were down 33% compared to Q3 2011, reflecting the impact of
an expected re-engineering of key areas of the Regenerative Medicine business including an
ongoing restructuring of the sales and marketing organization and the implementation of a
new commercial model, all of which is expected to position DERMAGRAFT for future sales
growth.

FIRAZYR – Hereditary Angioedema (“HAE”)

FIRAZYR sales continue to grow worldwide primarily driven by the strong launch in the
US market. We continue to see new patients starting treatment and high levels of repeat
usage by existing patients. The number of new patients and the irregular nature of HAE
attacks affects the rate of reorder and explains the variability in results quarter over
quarter as seen between Q3 and Q2 2012.

ADDERALL XR – ADHD

ADDERALL XR product sales decreased in Q3 2012 as a result of lower US prescription
demand following the introduction of a new generic competitor, higher sales deductions and
the effect of higher destocking in Q3 2012 compared to Q3 2011. These negative factors
were partially offset by the benefit of a price increase taken since Q3 2011.

Sales deductions in Q3 2012 (63% of gross product sales) were significantly higher
than Q3 2011 (47% of gross product sales) as Q3 2011 benefited from a lowering of the
estimate of inventory in the US retail pipeline and the related sales deduction reserve.

2. Royalties

                                                         Year on year growth
                                    Royalties to
        Product                       Shire $M       Royalties            CER
        FOSRENOL              1.00      14.0           +28%              +28%
        ADDERALL XR           1.00      11.2           -51%              -51%
        3TC(R) and ZEFFIX(R)  1.00      10.6           -39%              -39%
        Other                 1.00      6.0            -49%              -47%
        Total                 1.00      41.8           -33%              -33%

Royalties from ADDERALL XR in Q3 2012 were significantly impacted by a lower royalty
rate payable on sales of authorized generic ADDERALL XR by Impax, following the launch of
Actavis’ generic version.

Royalty income from 3TC and ZEFFIX continues to be adversely impacted by increased
competition from other products and the expiry of patents in certain territories. Also,
since Q2 2011 Shire has not recognised royalty income for 3TC and ZEFFIX for certain
territories due to a disagreement between GlaxoSmithKline (“GSK”), ViiV Healthcare
(“ViiV”) and Shire about how the relevant royalty rate should be applied given the expiry
dates of certain patents. In October 2012 Shire, GSK and ViiV settled this disagreement
and in Q4 2012 Shire will recognise one-time royalty income in respect of prior periods of
$38 million as a result.

3. Financial details

Cost of product sales

                                                    % of               % of
                                                 product            product
                                    Q3 2012        sales   Q3 2011    sales
                                         $M                     $M
        Cost of product sales (US
        GAAP)                         167.9          16%     166.5      16%
        Unwind of DERMAGRAFT
        inventory fair value
        step-up on acquisition            -                  (9.0)
        Transfer of manufacturing
        from Owings Mills                 -                  (3.4)
        Depreciation                  (9.4)                  (8.6)
        Cost of product sales (Non
        GAAP)                         158.5          15%     145.5      14%

Non GAAP cost of product sales as a percentage of product sales increased slightly in
Q3 2012 due to lower gross margins from DERMAGRAFT and ADDERALL XR compared with the same
period in 2011.

US GAAP cost of product sales as a percentage of product sales remained constant as
the impact of lower Non GAAP gross margins in Q3 2012 was offset by the fair value
adjustment for DERMAGRAFT inventories and costs incurred on the transfer of manufacturing
from Owings Mills in Q3 2011 which were not repeated in Q3 2012.

R&D

                                                 % of                % of
                                              product             product
                                    Q3 2012     sales   Q3 2011     sales
                                         $M                  $M
        R&D (US GAAP)                 224.7       21%     201.5       20%
        Impairment of intangible
        assets                            -              (16.0)
        Depreciation                  (5.5)               (5.6)
        R&D (Non GAAP)                219.2       21%     179.9       18%

Non GAAP R&D increased by $39.3 million, or 22%, due to our continuing investment in a
number of targeted R&D programs including new uses for LDX and our SPD602 program
(acquired with FerroKin Biosciences, Inc. (“FerroKin”)). On a CER basis Non GAAP R&D
increased by approximately 25%, a higher rate of increase than on a reported basis as Q3
2012 benefited from favorable foreign exchange.

US GAAP R&D increased by $23.2 million, or 12%, a lower rate of increase than on a Non
GAAP basis as Q3 2011 included certain IPR&D impairment charges not repeated in Q3 2012.

SG&A

                                                 % of                % of
                                              product             product
                                    Q3 2012     sales   Q3 2011     sales
                                         $M                  $M
        SG&A (US GAAP)                437.4       41%     452.1       44%
        Intangible asset
        amortization                 (50.0)              (46.4)
        Legal and litigation
        costs[(1)]                    (4.5)                   -
        Depreciation                 (14.2)              (16.7)
        SG&A (Non GAAP)               368.7       35%     389.0       38%

        1) During 2012 Shire amended its Non GAAP policy to exclude costs related to
          the settlement of litigation, government investigations and other disputes, together
          with related external legal costs. Non GAAP SG&A in Q3 2011 has not been restated as
          the amounts incurred in that period were not significant.

Non GAAP SG&A decreased by $20.3 million, or 5%, reflecting our continuing focus on
effective cost management. Reported costs also benefited (by 3 percentage points) from the
stronger dollar in the quarter.

US GAAP SG&A decreased by $14.7 million, or 3%, a lower rate of decrease than on a Non
GAAP basis as a result of higher intangible asset amortization and legal and litigation
costs excluded from Non GAAP SG&A.

Interest expense

For the three months to September 30, 2012 Shire incurred interest expense of $9.2
million (Q3 2011: $9.7 million). Interest expense in Q3 2012 principally relates to the
coupon on Shire’s $1,100 million 2.75% convertible bonds due 2014.

Other income/(expense), net

                                                    Q3 2012   Q3 2011
                                                         $M        $M
        Other income, net (US GAAP)                     3.5      15.6
        Gain on sale of investments                       -    (23.5)
        Other income/(expense), net (Non GAAP)          3.5     (7.9)

Other income/(expense), net in Q3 2012 included foreign exchange gains, compared to
foreign exchange losses in Q3 2011, reflecting volatility in a number of currencies to
which Shire has exposure.

Taxation

The effective rate of tax on Non GAAP income in Q3 2012 was 18% (Q3 2011: 25%), and on
a US GAAP basis the effective rate of tax was 15% (Q3 2011: 27%). The effective rate of
tax in Q3 2012 on both a Non GAAP and US GAAP basis is lower than the same period in 2011
due primarily to favorable changes in profit mix.

FINANCIAL INFORMATION

          i) TABLE OF CONTENTS

                                                                 Page
        Unaudited US GAAP Consolidated Balance Sheets              12
        Unaudited US GAAP Consolidated Statements of Income        13
        Unaudited US GAAP Consolidated Statements of Cash
        Flows                                                      15
        Selected Notes to the Unaudited US GAAP Financial
        Statements
        (1) Earnings per share                                     17
        (2) Analysis of revenues                                   18
        Non GAAP reconciliation                                    20

Unaudited US GAAP financial position as of September 30, 2012
Consolidated Balance Sheets

                                                       September 30,  December 31,
                                                                2012          2011
                                                                  $M            $M
        ASSETS
        Current assets:
        Cash and cash equivalents                            1,321.9         620.0
        Restricted cash                                         18.9          20.6
        Accounts receivable, net                               863.6         845.0
        Inventories                                            427.5         340.1
        Deferred tax asset                                     209.9         207.6
        Prepaid expenses and other current assets              143.5         174.9
        Total current assets                                 2,985.3       2,208.2
        Non-current assets:
        Investments                                             44.6          29.9
        Property, plant and equipment ("PP&E"), net            931.9         932.1
        Goodwill                                               639.2         592.6
        Other intangible assets, net                         2,593.6       2,493.0
        Deferred tax asset                                      42.4          50.7
        Other non-current assets                                79.5          73.7
        Total assets                                         7,316.5       6,380.2
        LIABILITIES AND EQUITY
        Current liabilities:
        Accounts payable and accrued expenses                1,446.9       1,370.5
        Convertible bonds                                          -       1,100.0
        Other current liabilities                               93.7          63.8
        Total current liabilities                            1,540.6       2,534.3
        Non-current liabilities:
        Convertible bonds                                    1,100.0             -
        Deferred tax liability                                 526.4         516.6
        Other non-current liabilities                          271.5         144.3
        Total liabilities                                    3,438.5       3,195.2
        Equity:
        Common stock of 5p par value; 1,000 million
        shares authorized; and 562.5 million shares
        issued and outstanding (2011: 1,000 million
        shares authorized; and 562.5 million shares
        issued and outstanding)                                 55.7          55.7
        Additional paid-in capital                           2,956.2       2,853.3
        Treasury stock: 6.6 million shares (2011: 11.8
        million)                                             (188.2)       (287.2)
        Accumulated other comprehensive income                  72.5          60.3
        Retained earnings                                      981.8         502.9
        Total equity                                         3,878.0       3,185.0
        Total liabilities and equity                         7,316.5       6,380.2

Unaudited US GAAP results for the three months and nine months to September 30, 2012
Consolidated Statements of Income

                                                               9 months   9 months
                                  3 months to    3 months to         to         to
                                                              September  September
                                September 30,  September 30,        30,        30,
                                         2012           2011       2012       2011
                                           $M             $M         $M         $M
        Revenues:
        Product sales                 1,054.5        1,018.4    3,309.1    2,901.0
        Royalties                        41.8           62.8      154.4      199.8
        Other revenues                    4.1            4.9       16.5       20.4
        Total revenues                1,100.4        1,086.1    3,480.0    3,121.2
        Costs and expenses:
        Cost of product
        sales[(1)]                      167.9          166.5      478.8      434.7
        R&D[(1)]                        224.7          201.5      683.6      556.3
        SG&A[(1)]                       437.4          452.1    1,448.4    1,295.3
        (Gain)/loss on sale of
        product rights                  (5.7)            0.3     (16.5)        3.8
        Reorganization costs                -            5.0          -       18.0
        Integration and
        acquisition costs                 2.7            5.3       15.1        7.9
        Total operating
        expenses                        827.0          830.7    2,609.4    2,316.0
        Operating income                273.4          255.4      870.6      805.2
        Interest income                   0.9            0.3        2.3        1.5
        Interest expense                (9.2)          (9.7)     (29.0)     (28.8)
        Other income, net                 3.5           15.6        3.6       15.9
        Total other
        (expense)/income, net           (4.8)            6.2     (23.1)     (11.4)
        Income before income
        taxes and equity in
        earnings of equity
        method investees                268.6          261.6      847.5      793.8
        Income taxes                   (41.6)         (69.5)    (144.6)    (187.3)
        Equity in earnings of
        equity method
        investees, net of taxes           0.2            0.8        0.5        3.2
        Net income                      227.2          192.9      703.4      609.7

        1) Cost of product sales includes amortization of intangible assets relating
          to favorable manufacturing contracts of $nil for the three months to September 30,
          2012 (2011: $0.5 million) and $0.7 million for the nine months to September 30, 2012
          (2011: $1.4 million). R&D includes intangible asset impairment charges of $nil (2011:
          $16.0 million) for the three months to September 30, 2012 and $27.0 million (2011:
          $16.0 million) for the nine months to September 30, 2012. SG&A costs include
          amortization of intangible assets relating to intellectual property rights acquired of
          $50.0 million for the three months to September 30, 2012 (2011: $46.4 million) and
          $146.6 million for the nine months to September 30, 2012 (2011: $119.1 million).

Unaudited US GAAP results for the three months and nine months to September 30, 2012
Consolidated Statements of Income (continued)

                                                               9 months   9 months
                                  3 months to    3 months to         to         to
                                                              September  September
                                September 30,  September 30,        30,        30,
                                         2012           2011       2012       2011
        Earnings per ordinary
        share - basic                   40.9c          35.0c     126.6c     110.6c
        Earnings per ADS -
        basic                          122.7c         105.0c     379.8c     331.8c
        Earnings per ordinary
        share - diluted                 39.6c          33.9c     122.4c     106.7c
        Earnings per ADS -
        diluted                        118.8c         101.7c     367.2c     320.1c
        Weighted average
        number of shares:
                                     Millions       Millions   Millions   Millions
        Basic                           555.9          551.3      555.5      551.2
        Diluted                         593.1          593.8      594.0      595.0

Unaudited US GAAP results for the three months and nine months to September 30, 2012
Consolidated Statements of Cash Flows

                                              3 months to          9 months to
                                             September 30,        September 30,

                                             2012        2011     2012        2011
                                               $M          $M       $M          $M

        CASH FLOWS FROM OPERATING
        ACTIVITIES:
        Net income                          227.2       192.9    703.4       609.7
        Adjustments to reconcile net
        income to net cash provided by
        operating activities:
                 Depreciation and
                 amortization                79.1        80.0    231.5       212.3
                 Share based compensation    21.6        19.8     65.0        54.7
                 Impairment of intangible
                 assets                         -        16.0     27.0        16.0
                 Gain on sale of
                 non-current investments        -      (23.5)        -      (23.5)
                 (Gain)/loss on sale of
                 product rights             (5.7)         0.3   (16.5)         3.8
                 Other                        0.5        11.7      5.1         5.9
        Movement in deferred taxes          (6.3)      (30.9)   (30.4)      (13.2)
        Equity in earnings of equity
        method investees                    (0.2)       (0.8)    (0.5)       (3.2)
        Changes in operating assets and
        liabilities:
                 Increase in accounts
                 receivable                (45.4)      (66.7)   (23.0)     (122.8)
                 Increase/(decrease) in
                 sales deduction accrual      8.5      (19.9)     36.1        46.2
                 Increase in inventory     (14.9)      (12.2)   (81.9)      (42.8)
                 (Increase)/decrease in
                 prepayments and other
                 assets                    (14.3)        31.1     17.8        17.3
                 Increase/(decrease) in
                 accounts payable and
                 other liabilities           38.3      (24.3)     72.7     (101.4)
        Returns on investment from joint
        venture                                 -         5.2      4.9         5.2
        Net cash provided by operating
        activities(A)                       288.4       178.7  1,011.2       664.2

        CASH FLOWS FROM INVESTING
        ACTIVITIES:
        Movements in restricted cash           (4.5)      0.9      1.7      5.7
        Purchases of subsidiary
        undertakings and businesses, net of
        cash acquired                              -    (3.8)   (97.0)  (723.5)
        Purchases of non-current
        investments                            (7.4)    (3.8)   (12.1)    (8.3)
        Purchases of PP&E                     (27.2)   (40.9)   (91.6)  (135.9)
        Purchases of intangible assets             -    (5.2)   (43.5)    (5.2)
        Proceeds from disposal of
        non-current investments and PP&E           -     94.7      4.6     94.7
        Proceeds from capital expenditure
        grants                                     -        -      8.4        -
        Proceeds received on sale of
        product rights                           3.3      1.9     13.7      8.8
        Returns of equity investments and
        proceeds from short term
        investments                              0.1      0.1      0.2      1.7
        Net cash (used in)/provided by
        investing activities[(B)]             (35.7)     43.9  (215.6)  (762.0)

Unaudited US GAAP results for the three months and nine months to September 30, 2012
Consolidated Statements of Cash Flows (continued)

                                            3 months to           9 months to
                                           September 30,         September 30,

                                           2012         2011      2012        2011
                                             $M           $M        $M          $M
        CASH FLOWS FROM FINANCING
        ACTIVITIES:
        Proceeds from drawing of
        revolving credit facility             -            -         -        30.0
        Repayment of revolving credit
        facility                              -       (30.0)         -      (30.0)
        Repayment of debt acquired
        through business combinations         -            -     (3.0)      (13.1)
        Excess tax benefit associated
        with exercise of stock options      3.5          4.9      38.6        23.7
        Payment of dividend                   -            -    (70.7)      (60.5)
        Payments to acquire shares by
        the Employee Benefit Trust
        ("EBT")                          (40.2)       (62.9)    (50.9)     (126.8)
        Other                             (3.3)        (0.5)     (2.6)       (0.1)
        Net cash used in financing
        activities[(C)]                  (40.0)       (88.5)    (88.6)     (176.8)
        Effect of foreign exchange
        rate changes on cash and cash
        equivalents [(D)]                 (3.5)        (2.3)     (5.1)         0.4
        Net increase/(decrease) in
        cash and cash equivalents[(A)
        +(B) +(C) +(D)]                   209.2        131.8     701.9     (274.2)
        Cash and cash equivalents at
        beginning of period             1,112.7        144.6     620.0       550.6
        Cash and cash equivalents at
        end of period                   1,321.9        276.4   1,321.9       276.4

Unaudited US GAAP results for the three months and nine months to September 30, 2012

Selected Notes to the Financial Statements

(1) Earnings Per Share (“EPS”)


                              3 months to    3 months to    9 months to    9 months to
                            September 30,  September 30,  September 30,  September 30,
                                     2012           2011           2012           2011
                                       $M             $M             $M             $M
        Numerator for basic
        EPS                         227.2          192.9          703.4          609.7
        Interest on
        convertible bonds,
        net of tax                    7.5            8.4           23.7           25.2
        Numerator for
        diluted EPS                 234.7          201.3          727.1          634.9
        Weighted average
        number of shares:
                                 Millions       Millions       Millions       Millions
        Basic(1)                    555.9          551.3          555.5          551.2
        Effect of dilutive
        shares:
        Share based awards
        to employees(2)               3.7            9.0            5.0           10.4
        Convertible bonds
        2.75% due 2014(3)            33.5           33.5           33.5           33.4
        Diluted                     593.1          593.8          594.0          595.0

        1) Excludes shares purchased by the EBT and presented by Shire as treasury
          stock.
        2) Calculated using the treasury stock method.
        3) Calculated using the "if converted" method.

The share equivalents not included in the calculation of the diluted weighted average
number of shares are shown below:


                              3 months to    3 months to    9 months to    9 months to

                            September 30,  September 30,  September 30,   September 30,
                                     2012           2011           2012            2011
                                 Millions       Millions       Millions        Millions
        Share based awards
        to employees[(1)]             6.6            3.2            4.9             3.9

        1) Certain stock options have been excluded from the calculation of diluted
          EPS because (a) their exercise prices exceeded Shire's average share price during the
          calculation period or (b) the required performance conditions were not satisfied as at
          the balance sheet date.

Unaudited US GAAP results for the three months to September 30, 2012

Selected Notes to the Financial Statements

(2) Analysis of revenues

        3 months to September 30,        2012     2011     2012        2012
                                                              %  % of total
                                           $M       $M   change     revenue
        Net product sales:
        Specialty Pharmaceuticals ("SP")
        Behavioral Health ("BH")
        VYVANSE                         247.1    199.7      24%         23%
        ADDERALL XR                     102.2    149.9     -32%          9%
        INTUNIV                          69.0     56.1      23%          6%
        EQUASYM(R)                        5.5      5.1       8%         <1%
                                        423.8    410.8       3%         39%
        Gastro Intestinal ("GI")
        LIALDA/MEZAVANT                 104.4     89.7      16%          9%
        PENTASA                          67.0     55.9      20%          6%
        RESOLOR(R)                        2.8      1.5      87%         <1%
                                        174.2    147.1      18%         16%
        General products
        FOSRENOL                         38.1     40.5      -6%          3%
        XAGRID(R)                        22.0     23.3      -6%          2%
                                         60.1     63.8      -6%          5%
        Other product sales              25.3     36.3     -30%          2%
        Total SP product sales          683.4    658.0       4%         62%
        HGT
        REPLAGAL                        121.7    129.0      -6%         11%
        ELAPRASE                        110.5    109.6       1%         10%
        VPRIV                            74.9     64.6      16%          7%
        FIRAZYR                          30.3      7.2     321%          3%
        Total HGT product sales         337.4    310.4       9%         31%
        Regenerative Medicine ("RM")
        DERMAGRAFT                       33.7     50.0     -33%          3%
        Total RM product sales           33.7     50.0     -33%          3%
        Total product sales           1,054.5  1,018.4       4%         96%
        Royalties:
        FOSRENOL                         14.0     10.9      28%          1%
        ADDERALL XR                      11.2     22.9     -51%          1%
        3TC and ZEFFIX                   10.6     17.3     -39%          1%
        Other                             6.0     11.7     -49%         <1%
        Total royalties                  41.8     62.8     -33%          4%
        Other revenues                    4.1      4.9     -16%         <1%
        Total revenues                1,100.4  1,086.1       1%        100%

Unaudited US GAAP results for the nine months to September 30, 2012

Selected Notes to the Financial Statements

(2) Analysis of revenues

        9 months to September 30,     2012      2011      2012        2012
                                                             %  % of total
                                        $M        $M    change     revenue
        Net product sales:
        SP
        BH
        VYVANSE                      773.3     587.9       32%         22%
        ADDERALL XR                  347.5     408.0      -15%         10%
        INTUNIV                      206.6     157.6       31%          6%
        EQUASYM                       21.3      15.6       37%         <1%
                                   1,348.7   1,169.1       15%         39%
        GI
        LIALDA/MEZAVANT              288.5     276.0        5%          8%
        PENTASA                      196.7     186.2        6%          6%
        RESOLOR                        8.3       4.0      108%         <1%
                                     493.5     466.2        6%         14%
        General products
        FOSRENOL                     126.8     127.0      <-1%          4%
        XAGRID                        70.7      69.2        2%          2%
                                     197.5     196.2        1%          6%
        Other product sales           85.9     117.3      -27%          2%
        Total SP product sales     2,125.6   1,948.8        9%         61%
        HGT
        REPLAGAL                     379.3     354.3        7%         11%
        ELAPRASE                     358.3     340.9        5%         10%
        VPRIV                        229.3     186.9       23%          7%
        FIRAZYR                       81.7      18.1      351%          2%
        Total HGT product sales    1,048.6     900.2       16%         30%
        RM
        DERMAGRAFT                   134.9      52.0      159%          4%
        Total RM product sales       134.9      52.0      159%          4%
        Total product sales        3,309.1   2,901.0       14%         95%
        Royalties:
        ADDERALL XR                   62.2      66.6       -7%          2%
        FOSRENOL                      37.0      31.4       18%          1%
        3TC and ZEFFIX                34.8      64.1      -46%          1%
        Other                         20.4      37.7      -46%         <1%
        Total royalties              154.4     199.8      -23%          4%
        Other revenues                16.5      20.4      -19%         <1%
        Total revenues             3,480.0   3,121.2       11%        100%

Unaudited results for the three months to September 30, 2012

Non GAAP reconciliation

        3 months to September                                                  Non
        30, 2012                US GAAP            Adjustments                GAAP
                                            (a)   (b)    (c)   (d)    (e)
                                     $M      $M    $M     $M    $M     $M       $M
        Total revenues          1,100.4       -     -      -     -      -  1,100.4
        Costs and expenses:
        Cost of product sales     167.9       -     -      -     -  (9.4)    158.5
        R&D                       224.7       -     -      -     -  (5.5)    219.2
        SG&A                      437.4  (50.0)     -      - (4.5) (14.2)    368.7
        Gain on sale of product
        rights                    (5.7)       -     -    5.7     -      -        -
        Integration and
        acquisition costs           2.7       - (2.7)      -     -      -        -
        Depreciation                  -       -     -      -     -   29.1     29.1
        Total operating
        expenses                  827.0  (50.0) (2.7)    5.7 (4.5)      -    775.5
        Operating income          273.4    50.0   2.7  (5.7)   4.5      -    324.9
        Interest income             0.9       -     -      -     -      -      0.9
        Interest expense          (9.2)       -     -      -     -      -    (9.2)
        Other income, net           3.5       -     -      -     -      -      3.5
        Total other expense,
        net                       (4.8)       -     -      -     -      -    (4.8)
        Income before income
        taxes and equity in
        earnings of equity
        method investees          268.6    50.0   2.7  (5.7)   4.5      -    320.1
        Income taxes             (41.6)  (14.3) (1.1)      - (1.5)      -   (58.5)
        Equity in earnings of
        equity method
        investees, net of tax       0.2       -     -      -     -      -      0.2
        Net income                227.2    35.7   1.6  (5.7)   3.0      -    261.8
        Impact of convertible
        debt, net of tax            7.5       -     -      -     -      -      7.5
        Numerator for diluted
        EPS                       234.7    35.7   1.6  (5.7)   3.0      -    269.3
        Weighted average number
        of shares (millions) -
        diluted                   593.1       -     -      -     -      -    593.1
        Diluted earnings per
        ADS                      118.8c   18.0c  0.9c (3.0c)  1.5c      -   136.2c

The following items are included in Adjustments:

        1) Amortization and asset impairments: Amortization of intangible assets
          relating to intellectual property rights acquired ($50.0 million), and tax effect of
          adjustments;
        2) Acquisition and integration activities: Costs associated with the acquisition
          of FerroKin and the integration of Advanced BioHealing Inc. ("ABH") ($1.5 million),
          charges related to the change in fair value of deferred contingent consideration ($1.2
          million), and tax effect of adjustments;
        3) Divestments, reorganizations and discontinued operations: Re-measurement of
          DAYTRANA contingent consideration to fair value ($5.7 million);
        4) Legal and litigation costs: Costs related to litigation, government
          investigations, other disputes and external legal costs ($4.5 million), and tax effect
          of adjustments; and
        5) Depreciation reclassification: Depreciation of $29.1 million included in Cost
          of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the
          presentation of Non GAAP earnings.

Unaudited results for the three months to September 30, 2011

Non GAAP reconciliation

        3 months to September 30,
        2011                        US GAAP          Adjustments          Non GAAP
                                                (a)    (b)    (c)    (d)
                                         $M      $M     $M     $M     $M        $M
        Total revenues              1,086.1       -      -      -      -   1,086.1
        Costs and expenses:
        Cost of product sales         166.5       -  (9.0)  (3.4)  (8.6)     145.5
        R&D                           201.5  (16.0)      -      -  (5.6)     179.9
        SG&A                          452.1  (46.4)      -      - (16.7)     389.0
        Loss on sale of product
        rights                          0.3       -      -  (0.3)      -         -
        Reorganization costs            5.0       -      -  (5.0)      -         -
        Integration and acquisition
        costs                           5.3       -  (5.3)      -      -         -
        Depreciation                      -       -      -      -   30.9      30.9
        Total operating expenses      830.7  (62.4) (14.3)  (8.7)      -     745.3
        Operating income              255.4    62.4   14.3    8.7      -     340.8
        Interest income                 0.3       -      -      -      -       0.3
        Interest expense              (9.7)       -      -      -      -     (9.7)
        Other income/(expense), net    15.6       -      - (23.5)      -     (7.9)
        Total other
        income/(expense), net           6.2       -      - (23.5)      -    (17.3)
        Income before income taxes
        and equity in earnings of
        equity method investees       261.6    62.4   14.3 (14.8)      -     323.5
        Income taxes                 (69.5)  (16.4)  (2.9)    9.2      -    (79.6)
        Equity in earnings of
        equity method investees,
        net of tax                      0.8       -      -      -      -       0.8
        Net income                    192.9    46.0   11.4  (5.6)      -     244.7
        Impact of convertible debt,
        net of tax                      8.4       -      -      -      -       8.4
        Numerator for diluted EPS     201.3    46.0   11.4  (5.6)      -     253.1
        Weighted average number of
        shares (millions) - diluted   593.8       -      -      -      -     593.8
        Diluted earnings per ADS     101.7c   23.2c   5.8c (2.8c)      -    127.9c

The following items are included in Adjustments:

        1) Amortization and asset impairments: Impairment of intangible assets
          ($16.0 million), amortization of intangible assets relating to intellectual property
          rights acquired ($46.4 million), and tax effect of adjustments;
        2) Acquisition and integration activities: Unwind of ABH inventory step-up ($9.0
          million), costs associated with the acquisition and integration of ABH ($3.6 million)
          and integration of Movetis ($1.7 million), and tax effect of adjustments;
        3) Divestments, reorganizations and discontinued operations: Accelerated
          depreciation ($2.2 million) and dual running costs ($1.2 million) on the transfer of
          manufacturing from Owings Mills to a third party, re-measurement of DAYTRANA
          contingent consideration to fair value ($0.3 million), reorganization costs ($5.0
          million) on the transfer of manufacturing from Owings Mills to a third party and
          establishment of an international commercial hub in Switzerland, gain on disposal of
          investment in Vertex Pharmaceuticals Inc. ("Vertex") ($23.5 million), and tax effect
          of adjustments; and
        4) Depreciation: Depreciation of $30.9 million included in Cost of product
          sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation
          of Non GAAP earnings.

Unaudited results for the nine months to September 30, 2012

Non GAAP reconciliation

        9 months to                                                            Non
        September 30, 2012   US GAAP              Adjustments                 GAAP
                                          (a)    (b)    (c)    (d)    (e)
                                  $M       $M     $M     $M     $M     $M       $M
        Total revenues       3,480.0        -      -      -      -      -  3,480.0
        Costs and expenses:
        Cost of product
        sales                  478.8        -      -      -      - (23.6)    455.2
        R&D                    683.6   (27.0) (23.0)      -      - (18.3)    615.3
        SG&A                 1,448.4  (146.6)      -      - (40.4) (42.3)  1,219.1
        Gain on sale of
        product rights        (16.5)        -      -   16.5      -      -        -
        Integration and
        acquisition costs       15.1        - (15.1)      -      -      -        -
        Depreciation               -        -      -      -      -   84.2     84.2
        Total operating
        expenses             2,609.4  (173.6) (38.1)   16.5 (40.4)      -  2,373.8
        Operating income       870.6    173.6   38.1 (16.5)   40.4      -  1,106.2
        Interest income          2.3        -      -      -      -      -      2.3
        Interest expense      (29.0)        -      -      -      -      -   (29.0)
        Other income, net        3.6        -      -      -      -      -      3.6
        Total other expense,
        net                   (23.1)        -      -      -      -      -   (23.1)
        Income before income
        taxes and equity in
        earnings of equity
        method investees       847.5    173.6   38.1 (16.5)   40.4      -  1,083.1
        Income taxes         (144.6)   (42.0) (10.1)      - (14.5)      -  (211.2)
        Equity in earnings
        of equity method
        investees, net of
        tax                      0.5        -      -      -      -      -      0.5
        Net income             703.4    131.6   28.0 (16.5)   25.9      -    872.4
        Impact of
        convertible debt,
        net of tax              23.7        -      -      -      -      -     23.7
        Numerator for
        diluted EPS            727.1    131.6   28.0 (16.5)   25.9      -    896.1
        Weighted average
        number of shares
        (millions) - diluted   594.0        -      -      -      -      -    594.0
        Diluted earnings per
        ADS                   367.2c    66.6c  14.1c (8.4c)  13.2c      -   452.7c

The following items are included in Adjustments:

        1) Amortization and asset impairments: Impairment of IPR&D intangible assets
          for RESOLOR ($27.0 million), amortization of intangible assets relating to
          intellectual property rights acquired ($146.6 million), and tax effect of adjustments;
        2) Acquisitions and integration activities: Up-front payments made to Sangamo
          Biosciences Inc. and for the acquisition of the US rights to prucalopride (marketed in
          certain countries in Europe as RESOLOR) ($23.0 million), costs associated with
          acquisition of FerroKin and the integration of ABH ($11.8 million), charges related to
          the change in fair value of deferred contingent consideration ($3.3 million), and tax
          effect of adjustments;
        3) Divestments, reorganizations and discontinued operations: Re-measurement of
          DAYTRANA contingent consideration to fair value ($16.5 million);
        4) Legal and litigation costs: Costs related to the litigation, government
          investigations, other disputes and external legal costs ($40.4 million), and tax
          effect of adjustments; and
        5) Depreciation reclassification: Depreciation of $84.2 million included in Cost
          of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the
          presentation of Non GAAP earnings.

Unaudited results for the nine months to September 30, 2011

Non GAAP reconciliation

        9 months to September 30,
        2011                       US GAAP          Adjustments           Non GAAP
                                                (a)    (b)    (c)    (d)
                                        $M       $M     $M     $M     $M        $M
        Total revenues             3,121.2        -      -      -      -   3,121.2
        Costs and expenses:
        Cost of product sales        434.7        -  (9.0)  (9.0) (22.4)     394.3
        R&D                          556.3   (16.0)      -      - (16.4)     523.9
        SG&A                       1,295.3  (119.1)      -      - (46.4)   1,129.8
        Loss on sale of product
        rights                         3.8        -      -  (3.8)      -         -
        Reorganization costs          18.0        -      - (18.0)      -         -
        Integration and
        acquisition costs              7.9        -  (7.9)      -      -         -
        Depreciation                     -        -      -      -   85.2      85.2
        Total operating expenses   2,316.0  (135.1) (16.9) (30.8)      -   2,133.2
        Operating income             805.2    135.1   16.9   30.8      -     988.0
        Interest income                1.5        -      -      -      -       1.5
        Interest expense            (28.8)        -      -      -      -    (28.8)
        Other income/(expense),
        net                           15.9      2.4      - (23.5)      -     (5.2)
        Total other expense, net    (11.4)      2.4      - (23.5)      -    (32.5)
        Income before income taxes
        and equity in earnings of
        equity method investees      793.8    137.5   16.9    7.3      -     955.5
        Income taxes               (187.3)   (35.6)  (4.2)    4.5      -   (222.6)
        Equity in earnings of
        equity method investees,
        net of tax                     3.2        -      -      -      -       3.2
        Net income                   609.7    101.9   12.7   11.8      -     736.1
        Impact of convertible
        debt, net of tax              25.2        -      -      -      -      25.2
        Numerator for diluted EPS    634.9    101.9   12.7   11.8      -     761.3
        Weighted average number of
        shares (millions) -
        diluted                      595.0        -      -      -      -     595.0
        Diluted earnings per ADS    320.1c    51.4c   6.4c   5.9c      -    383.8c

The following items are included in Adjustments:

        1) Amortization and asset impairments: Impairment of intangible assets
          ($16.0 million), amortization of intangible assets relating to intellectual property
          rights acquired ($119.1 million), impairment of available for sale securities ($2.4
          million), and tax effect of adjustments;
        2) Acquisitions and integration activities: Unwind of ABH inventory step-up
          ($9.0 million), costs associated with acquisition and integration of ABH ($10.5
          million) and integration of Movetis ($5.6 million), less adjustment to contingent
          consideration payable for EQUASYM ($8.2 million), and tax effect of adjustments;
        3) Divestments, reorganizations and discontinued operations: Accelerated
          depreciation ($6.6 million) and dual running costs ($2.4 million) on the transfer of
          manufacturing from Owings Mills to a third party, re-measurement of DAYTRANA
          contingent consideration to fair value ($3.8 million), reorganization costs ($18.0
          million) on the transfer of manufacturing from Owings Mills to a third party and the
          establishment of an international commercial hub in Switzerland, gain on disposal of
          investment in Vertex ($23.5 million), and tax effect of adjustments; and
        4) Depreciation: Depreciation of $85.2 million included in Cost of product
          sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation
          of Non GAAP earnings.

Unaudited results for the three months and nine months to September 30, 2012

Non GAAP reconciliation

The following table reconciles US GAAP net cash provided by operating activities to
Non GAAP cash generation:

                                3 months to September     9 months to September
                                         30,                       30,
                                     2012          2011        2012          2011
                                       $M            $M          $M            $M
        Net cash provided by
        operating activities        288.4         178.7     1,011.2         664.2
        Tax and interest
        payments, net                66.8         117.2       150.9         280.0
        Up-front payments in
        respect of in-licensed
        and acquired products           -             -        23.0             -
        Non GAAP cash
        generation                  355.2         295.9     1,185.1         944.2

The following table reconciles US GAAP net cash provided by operating activities to
Non GAAP free cash flow:

                                3 months to September     9 months to September
                                         30,                       30,
                                     2012          2011        2012          2011
                                       $M            $M          $M            $M
        Net cash provided by
        operating activities        288.4         178.7     1,011.2         664.2
        Up-front payments in
        respect of in-licensed
        and acquired products           -             -        23.0             -
        Capital expenditure        (27.2)        (40.9)      (91.6)       (135.9)
        Non GAAP free cash
        flow                        261.2         137.8       942.6         528.3

Non GAAP net cash/(debt) comprises:

                                               September 30,  December 31,
                                                        2012          2011
                                                          $M            $M
        Cash and cash equivalents                    1,321.9         620.0
        Convertible bonds                          (1,100.0)     (1,100.0)
        Other debt                                     (9.4)         (8.2)
        Non GAAP net cash/(debt)                       212.5       (488.2)

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients’ needs, we develop and provide healthcare
in the areas of:

        - Behavioral Health and Gastro Intestinal conditions
        - Rare Diseases
        - Regenerative Medicine

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for patients,
physicians, policymakers, payors and our shareholders.

http://www.shire.com

THE “SAFEHARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking
statements. Such forward-looking statements involve a number of risks and uncertainties
and are subject to change at any time. In the event such risks or uncertainties
materialize, Shire’s results could be materially adversely affected. The risks and
uncertainties include, but are not limited to, risks associated with: the inherent
uncertainty of research, development, approval, reimbursement, manufacturing and
commercialization of Shire’s Specialty Pharmaceuticals, Human Genetic Therapies and
Regenerative Medicine products, as well as the ability to secure new products for
commercialization and/or development; government regulation of Shire’s products; Shire’s
ability to manufacture its products in sufficient quantities to meet demand; the impact of
competitive therapies on Shire’s products; Shire’s ability to register, maintain and
enforce patents and other intellectual property rights relating to its products; Shire’s
ability to obtain and maintain government and other third-party reimbursement for its
products; and other risks and uncertainties detailed from time to time in Shire’s filings
with the Securities and Exchange Commission.

Non GAAP Measures

This press release contains financial measures not prepared in accordance with US
GAAP. These measures are referred to as “Non GAAP” measures and include: Non GAAP
operating income; Non GAAP net income; Non GAAP diluted earnings per ADS; effectivetax
rate on Non GAAP income before income taxes and earnings of equity method investees
(“Effective tax rate on Non GAAP income”); Non GAAP cost of product sales; Non GAAP
research and development; Non GAAP selling, general and administrative; Non GAAP other
income/expense; Non GAAP cash generation; Non GAAP free cash flow and Non GAAP net
cash/(debt). These Non GAAP measures exclude the effect of certain cash and non-cash
items, that Shire’s management believes are not related to the core performance of Shire’s
business.

These Non GAAP financial measures are used by Shire’s management to make operating
decisions because they facilitate internal comparisons of Shire’s performance to
historical results and to competitors’ results. Shire’s Remuneration Committee uses
certain key Non GAAP measures when assessing the performance and compensation of
employees, including Shire’s executive directors.

The Non GAAP measures are presented in this press release as Shire’s management
believe that they will provide investors with a means of evaluating, and an understanding
of how Shire’s management evaluates, Shire’s performance and results on a comparable basis
that is not otherwise apparent on a US GAAP basis, since many non-recurring, infrequent or
non-cash items that Shire’s management believe are not indicative of the core performance
of the business may not be excluded when preparing financial measures under US GAAP.

These Non GAAP measures should not be considered in isolation from, as substitutes
for, or superior to financial measures prepared in accordance with US GAAP.

Where applicable the following items, including their tax effect, have been excluded
when calculating Non GAAP earnings for both 2012 and 2011, and from our Outlook:

Amortization and asset impairments:

        - Intangible asset amortization and impairment charges; and
        - Other than temporary impairment of investments.

Acquisitions and integration activities:

        - Up-front payments and milestones in respect of in-licensed and acquired
          products;
        - Costs associated with acquisitions, including transaction costs, fair value
          adjustments on contingent consideration and acquired inventory;
        - Costs associated with the integration of companies; and
        - Noncontrolling interests in consolidated variable interest entities.

Divestments, re-organizations and discontinued operations:

        - Gains and losses on the sale of non-core assets;
        - Costs associated with restructuring and re-organization activities;
        - Termination costs; and
        - Income/(losses) from discontinued operations.

Legal and litigation costs:

        - Net legal costs related to the settlement of litigation, government
          investigations and other disputes (excluding internal legal team costs).

Depreciation, which is included in Cost of product sales, R&D and SG&A costs in our US
GAAP results, has been separately disclosed for the presentation of 2011 and 2012 Non GAAP
earnings.

Cash generation represents net cash provided by operating activities, excluding
up-front and milestone payments for in-licensed and acquired products, tax and interest
payments.

Free cash flow represents net cash provided by operating activities, excluding
up-front and milestone payments for in-licensed and acquired products, but including
capital expenditure in the ordinary course of business.

A reconciliation of Non GAAP financial measures to the most directly comparable
measure under US GAAP is presented on pages 20 to 24.

Sales growth at CER, which is a Non GAAP measure, is computed by restating 2012
results using average 2011 foreign exchange rates for the relevant period.

Average exchange rates for the nine months to September 30, 2012 were $1.58:GBP1.00
and $1.29:EUR1.00 (2011: $1.61:GBP1.00 and $1.41:EUR1.00). Average exchange rates for Q3
2012 were $1.58:GBP1.00 and $1.25:EUR1.00 (2011: $1.61:GBP1.00 and $1.41:EUR1.00).

TRADEMARKS

All trademarks designated (R) and (TM) used in this press release are trademarks of
Shire plc or companies within the Shire group except for 3TC(R) and ZEFFIX(R) which are
trademarks of GSK, PENTASA(R) which is a registered trademark of FERRING B.V.,
FABRAZYME(R) and CEREZYME(R) which are trademarks of Genzyme Corporation, LIALDA(R) and
MEZAVANT(R) which are trademarks of Giuliani International Limited and DAYTRANA(R) which
is a trade mark of Noven Pharmaceuticals Inc. Certain trademarks of Shire plc or companies
within the Shire group are set out in Shire’s Annual Report on Form 10-K for the year
ended December 31, 2011 and the Quarterly Report on Form 10-Q for the three and six months
ended June 30, 2012.

For further information please contact:

        Investor Relations
              - Eric Rojas                 erojas@shire.com      +1-781-482-0999

              - Sarah Elton-Farr           seltonfarr@shire.com +44-1256-894-157
        Media

              - Jessica Mann               jmann@shire.com      +44-1256-894-280
              - Gwen Fisher                gfisher@shire.com     +1-484-595-9836
              - Jessica Cotrone            jcotrone@shire.com    +1-781-482-9538

SOURCE Shire plc


Source: PR Newswire